Archived: abiraterone (Zytiga)
Following a full submission
abiraterone acetate 250mg tablets (Zytiga®) is not recommended for use within NHS Scotland.
Indication under review: with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
Abiraterone plus prednisone was associated with significantly improved overall survival compared with placebo plus prednisone in patients with mCRPC previously treated with docetaxel.
The submitting company’s justification of the treatment’s costs in relation to its health benefits was not sufficient to gain acceptance by SMC. In addition, the submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
|Drug Name:||abiraterone (Zytiga)|
|SMC Drug ID:||764/12|
|Indication:||for the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.|
|Sub Category:||8.3 Sex hormones and hormone antagonists in malignant disease|
|Submission Type:||Full submission|
|Date Advice Published:||12 March 2012|
|abiraterone (Zytiga) Resubmission||Resubmission||13 August 2012|